BioSpecifics Technologies Corp. is a biopharmaceutical company that is the originator of collagenase-based therapies with injectable collagenase for twelve clinical indications to date. Injectable collagenase (collagenase clostridium histolyticum or CCH) is marketed as XIAFLEXÂŽ in the U.S. for the treatment of Dupuytren's contracture and Peyronie's disease by BioSpecifics' partner, Endo International plc (Endo). XIAFLEXÂŽ is also commercialized in Japan, Europe, Canada and Australia for Dupuytrenâs contracture and for Peyronie's disease in Canada, Europe and Australia.
Source
